179 related articles for article (PubMed ID: 26587663)
1. Impaired NFKBIE gene function decreases cellular uptake of methotrexate by down-regulating SLC19A1 expression in a human rheumatoid arthritis cell line.
Imamura H; Yoshina S; Ikari K; Miyazawa K; Momohara S; Mitani S
Mod Rheumatol; 2016 Jul; 26(4):507-16. PubMed ID: 26587663
[TBL] [Abstract][Full Text] [Related]
2. Expression of methotrexate transporters and metabolizing enzymes in rheumatoid synovial tissue.
Stamp LK; Hazlett J; Highton J; Hessian PA
J Rheumatol; 2013 Sep; 40(9):1519-22. PubMed ID: 23858048
[TBL] [Abstract][Full Text] [Related]
3. Functional variants in NFKBIE and RTKN2 involved in activation of the NF-κB pathway are associated with rheumatoid arthritis in Japanese.
Myouzen K; Kochi Y; Okada Y; Terao C; Suzuki A; Ikari K; Tsunoda T; Takahashi A; Kubo M; Taniguchi A; Matsuda F; Ohmura K; Momohara S; Mimori T; Yamanaka H; Kamatani N; Yamada R; Nakamura Y; Yamamoto K
PLoS Genet; 2012 Sep; 8(9):e1002949. PubMed ID: 23028356
[TBL] [Abstract][Full Text] [Related]
4. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.
Lima A; Bernardes M; Azevedo R; Monteiro J; Sousa H; Medeiros R; Seabra V
Toxicol Sci; 2014 Nov; 142(1):196-209. PubMed ID: 25124723
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis.
Blits M; Jansen G; Assaraf YG; van de Wiel MA; Lems WF; Nurmohamed MT; van Schaardenburg D; Voskuyl AE; Wolbink GJ; Vosslamber S; Verweij CL
Arthritis Rheum; 2013 Nov; 65(11):2791-802. PubMed ID: 23897011
[TBL] [Abstract][Full Text] [Related]
6. MiR-595 Suppresses the Cellular Uptake and Cytotoxic Effects of Methotrexate by Targeting SLC19A1 in CEM/C1 Cells.
Wang SM; Sun LL; Wu WS; Yan D
Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):8-13. PubMed ID: 29345051
[TBL] [Abstract][Full Text] [Related]
7. Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy.
Chatzikyriakidou A; Georgiou I; Voulgari PV; Papadopoulos CG; Tzavaras T; Drosos AA
Rheumatol Int; 2007 Sep; 27(11):1057-61. PubMed ID: 17404734
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients.
Bohanec Grabar P; Leandro-García LJ; Inglada-Pérez L; Logar D; Rodríguez-Antona C; Dolžan V
Pharmacogenomics; 2012 Nov; 13(14):1583-94. PubMed ID: 23148635
[TBL] [Abstract][Full Text] [Related]
9. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis.
Li X; Hu M; Li W; Gu L; Chen M; Ding H; Vanarsa K; Du Y
Int Immunopharmacol; 2016 Sep; 38():8-15. PubMed ID: 27233001
[TBL] [Abstract][Full Text] [Related]
10. Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population.
Lv S; Fan H; Yang H; Huang J; Li J; Shu X; Zhang L; Xu Y; Li X; Zuo J; Lv C; Kong X; Xiao C
J Clin Pharmacol; 2019 Nov; 59(11):1471-1476. PubMed ID: 31099054
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate affects HMGB1 expression in rheumatoid arthritis, and the downregulation of HMGB1 prevents rheumatoid arthritis progression.
Li YB; Xu P; Xu K; Cai YS; Sun MY; Yang L; Sun J; Lu SM
Mol Cell Biochem; 2016 Sep; 420(1-2):161-70. PubMed ID: 27522665
[TBL] [Abstract][Full Text] [Related]
12. Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study.
Hakamata J; Kaneko Y; Shimizu M; Yamaoka K; Maruyama J; Takeuchi T; Mochizuki M; Hashiguchi M
Biol Pharm Bull; 2018; 41(9):1414-1422. PubMed ID: 30175777
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients.
Moya P; Salazar J; Arranz MJ; Díaz-Torné C; del Río E; Casademont J; Corominas H; Baiget M
Pharmacogenomics; 2016; 17(1):25-9. PubMed ID: 26652611
[TBL] [Abstract][Full Text] [Related]
14. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients.
Lima A; Bernardes M; Sousa H; Azevedo R; Costa L; Ventura F; Seabra V; Medeiros R
Pharmacogenomics; 2014 Apr; 15(6):807-20. PubMed ID: 24350725
[TBL] [Abstract][Full Text] [Related]
15. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis.
Hayashi H; Tazoe Y; Tsuboi S; Horino M; Morishita M; Arai T; Ohshima M; Matsuyama T; Kosuge K; Yamada H; Tsuji D; Inoue K; Itoh K
Drug Metab Pharmacokinet; 2013; 28(2):164-8. PubMed ID: 22971639
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate-mediated inhibition of nuclear factor κB activation by distinct pathways in T cells and fibroblast-like synoviocytes.
Spurlock CF; Gass HM; Bryant CJ; Wells BC; Olsen NJ; Aune TM
Rheumatology (Oxford); 2015 Jan; 54(1):178-87. PubMed ID: 25118313
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model.
Hashizume M; Yoshida H; Tanaka K; Suzuki M; Matsumoto I; Sumida T; Mihara M
Arthritis Res Ther; 2012 Apr; 14(2):R96. PubMed ID: 22546471
[TBL] [Abstract][Full Text] [Related]
18. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts.
Suzuki K; Yoshida K; Ueha T; Kaneshiro K; Nakai A; Hashimoto N; Uchida K; Hashimoto T; Kawasaki Y; Shibanuma N; Nakagawa N; Sakai Y; Hashiramoto A
Arthritis Res Ther; 2018 Mar; 20(1):55. PubMed ID: 29566767
[TBL] [Abstract][Full Text] [Related]
20. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.
Ducreux J; Durez P; Galant C; Nzeusseu Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
Arthritis Rheumatol; 2014 Jan; 66(1):15-23. PubMed ID: 24449571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
